FrançaisBioMarin Pharmaceutical (BMRN): financial analysis & fundamentals
📈 See the interactive version (live chart) →
Valuation & profitability
| Metric | Value | What it means |
|---|---|---|
| P/E (price / earnings) | 176.5 | The higher, the more growth the market expects. |
| Forward P/E | 10.1 | On next year's expected earnings. Lower than current P/E = rising earnings. |
| PEG (P/E ÷ growth) | — | Below 1 = cheap given growth; above 2 = expensive. |
| Net margin | 2% | Share of revenue that ends up as profit. |
| Revenue growth | 20% | Pace of revenue growth. |
| Price-to-book | 2.0 | Price relative to book value. |
| Market cap | $12.6 B | Total market value of the company. |
| Dividend yield | — | No dividend currently. |
Income statement (by year)
| Year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2022 | $2.1 B | $142 M | 7% |
| 2023 | $2.4 B | $168 M | 7% |
| 2024 | $2.9 B | $427 M | 15% |
| 2025 | $3.2 B | $349 M | 11% |
📊 Open the interactive BioMarin Pharmaceutical page (charts, live news) →
Frequently asked questions
Is BioMarin Pharmaceutical stock expensive?
BioMarin Pharmaceutical has a P/E of 176.5 (forward P/E 10.1) and a PEG of —. A PEG below 1 is rather cheap given growth, above 2 is expensive. Verdict: valuation to review.
What is BioMarin Pharmaceutical's net margin?
BioMarin Pharmaceutical's net margin is about 2% — the share of revenue that ends up as net profit.
What is BioMarin Pharmaceutical's revenue?
Latest known revenue: $3.2 B for net income of $349 M. The year-by-year breakdown is in the income statement above.
What is BioMarin Pharmaceutical's market cap?
BioMarin Pharmaceutical (BMRN) has a market cap of about $12.6 B.
Does BioMarin Pharmaceutical pay a dividend?
No, BioMarin Pharmaceutical does not currently pay a dividend (it reinvests earnings).
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
- 🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
- 🎯 What to buy: 3 backtested methods over 6 years, from cautious to aggressive
- 💬 AI assistant: ask anything about any stock, with the numbers
- 📊 Portfolio tracking + 🔔 price alerts by email
⚠️ Educational information, not investment advice. Data: Yahoo Finance, recomputed by JPI Invest. A stock can be « cheap » for a bad reason.